Literature DB >> 25155823

The poorly membrane permeable antipsychotic drugs amisulpride and sulpiride are substrates of the organic cation transporters from the SLC22 family.

Joao N Dos Santos Pereira1, Sina Tadjerpisheh, Manar Abu Abed, Ali R Saadatmand, Babette Weksler, Ignacio A Romero, Pierre-Olivier Couraud, Jürgen Brockmöller, Mladen V Tzvetkov.   

Abstract

Variations in influx transport at the blood-brain barrier might affect the concentration of psychotropic drugs at their site of action and as a consequence might alter therapy response. Furthermore, influx transporters in organs such as the gut, liver and kidney may influence absorption, distribution, and elimination. Here, we analyzed 30 commonly used psychotropic drugs using a parallel artificial membrane permeability assay. Amisulpride and sulpiride showed the lowest membrane permeability (P e < 1.5 × 10(-6) cm/s) and will require influx transport to penetrate the blood-brain barrier and other physiological barriers. We then studied the uptake of amisulpride and sulpiride by the organic cation transporters of the SLC22 family OCT1, OCT2, OCT3, OCTN1, and OCTN2 Amisulpride was found to be transported by all five transporters studied. In contrast, sulpiride was only transported by OCT1 and OCT2. OCT1 showed the highest transport ability both for amisulpride (CLint = 1.9 ml/min/mg protein) and sulpiride (CLint = 4.2 ml/min/mg protein) and polymorphisms in OCT1 significantly reduced the uptake of both drugs. Furthermore, we observed carrier-mediated uptake that was inhibitable by known OCT inhibitors in the immortalized human brain microvascular endothelial cell line hCMEC/D3. In conclusion, this study demonstrates that amisulpride and sulpiride are substrates of organic cation transporters of the SLC22 family. SLC22 transporters may play an important role in the distribution of amisulpride and sulpiride, including their ability to penetrate the blood-brain barrier.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25155823      PMCID: PMC4389740          DOI: 10.1208/s12248-014-9649-9

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  52 in total

1.  BDDCS applied to over 900 drugs.

Authors:  Leslie Z Benet; Fabio Broccatelli; Tudor I Oprea
Journal:  AAPS J       Date:  2011-08-05       Impact factor: 4.009

Review 2.  Physiology of blood-brain interfaces in relation to brain disposition of small compounds and macromolecules.

Authors:  N Strazielle; J F Ghersi-Egea
Journal:  Mol Pharm       Date:  2013-01-23       Impact factor: 4.939

3.  The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1.

Authors:  Ali R Saadatmand; Sina Tadjerpisheh; Jürgen Brockmöller; Mladen V Tzvetkov
Journal:  Biochem Pharmacol       Date:  2012-02-10       Impact factor: 5.858

Review 4.  Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy.

Authors:  Anne T Nies; Hermann Koepsell; Katja Damme; Matthias Schwab
Journal:  Handb Exp Pharmacol       Date:  2011

5.  Cloning and characterization of two human polyspecific organic cation transporters.

Authors:  V Gorboulev; J C Ulzheimer; A Akhoundova; I Ulzheimer-Teuber; U Karbach; S Quester; C Baumann; F Lang; A E Busch; H Koepsell
Journal:  DNA Cell Biol       Date:  1997-07       Impact factor: 3.311

6.  Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites.

Authors:  Brandon Swift; Noelia Nebot; Jin Kyung Lee; Tianxiang Han; William R Proctor; Dhiren R Thakker; Dieter Lang; Martin Radtke; Mark J Gnoth; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2013-03-12       Impact factor: 3.922

7.  Determination of tiapride in human plasma using hydrophilic interaction liquid chromatography-tandem mass spectrometry.

Authors:  Ya Moon; In Bok Paek; Hui-Hyun Kim; Hye Young Ji; Hye Won Lee; Hyoung-Geun Park; Hye Suk Lee
Journal:  Arch Pharm Res       Date:  2004-09       Impact factor: 4.946

8.  Quantitative targeted absolute proteomic analysis of transporters, receptors and junction proteins for validation of human cerebral microvascular endothelial cell line hCMEC/D3 as a human blood-brain barrier model.

Authors:  Sumio Ohtsuki; Chiemi Ikeda; Yasuo Uchida; Yumi Sakamoto; Florence Miller; Fabienne Glacial; Xavier Decleves; Jean-Michel Scherrmann; Pierre-Olivier Couraud; Yoshiyuki Kubo; Masanori Tachikawa; Tetsuya Terasaki
Journal:  Mol Pharm       Date:  2012-12-11       Impact factor: 4.939

9.  Profiling solute carrier transporters in the human blood-brain barrier.

Authors:  E G Geier; E C Chen; A Webb; A C Papp; S W Yee; W Sadee; K M Giacomini
Journal:  Clin Pharmacol Ther       Date:  2013-09-05       Impact factor: 6.875

10.  A simple method for assessing free brain/free plasma ratios using an in vitro model of the blood brain barrier.

Authors:  Maxime Culot; Anaëlle Fabulas-da Costa; Emmanuel Sevin; Erica Szorath; Stefan Martinsson; Mila Renftel; Yan Hongmei; Romeo Cecchelli; Stefan Lundquist
Journal:  PLoS One       Date:  2013-12-03       Impact factor: 3.240

View more
  23 in total

1.  Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin Concentrations and Body Weight Gain by Pharmacokinetic/Pharmacodynamic Analyses.

Authors:  Anaïs Glatard; Monia Guidi; Aurélie Delacrétaz; Céline Dubath; Claire Grosu; Nermine Laaboub; Armin von Gunten; Philippe Conus; Chantal Csajka; Chin B Eap
Journal:  Clin Pharmacokinet       Date:  2020-03       Impact factor: 6.447

2.  The differential actions of clozapine and other antipsychotic drugs on the translocation of dopamine D2 receptors to the cell surface.

Authors:  Joseph M Schrader; Craig M Irving; J Christopher Octeau; Joseph A Christian; Timothy J Aballo; Dean J Kareemo; Joseph Conti; Jodi L Camberg; J Robert Lane; Jonathan A Javitch; Abraham Kovoor
Journal:  J Biol Chem       Date:  2019-01-22       Impact factor: 5.157

Review 3.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

4.  Modeling and Simulation for Individualized Therapy of Amisulpride in Chinese Patients with Schizophrenia: Focus on Interindividual Variability, Therapeutic Reference Range and the Laboratory Alert Level.

Authors:  Shanqing Huang; Lu Li; Zhanzhang Wang; Tao Xiao; Xiaolin Li; Shujing Liu; Ming Zhang; Haoyang Lu; Yuguan Wen; Dewei Shang
Journal:  Drug Des Devel Ther       Date:  2021-09-14       Impact factor: 4.162

Review 5.  A systematic review and combined meta-analysis of concentration of oral amisulpride.

Authors:  Lin Li; Lu Li; De-Wei Shang; Yu-Guan Wen; Yu-Ping Ning
Journal:  Br J Clin Pharmacol       Date:  2020-03-03       Impact factor: 4.335

Review 6.  Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions.

Authors:  C Arimany-Nardi; H Koepsell; M Pastor-Anglada
Journal:  Pharmacogenomics J       Date:  2015-11-03       Impact factor: 3.550

Review 7.  Transport of Drugs and Endogenous Compounds Mediated by Human OCT1: Studies in Single- and Double-Transfected Cell Models.

Authors:  Bastian Haberkorn; Martin F Fromm; Jörg König
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

8.  The Antipsychotic Drug Clozapine Suppresses the RGS4 Polyubiquitylation and Proteasomal Degradation Mediated by the Arg/N-Degron Pathway.

Authors:  Jun Hyoung Jeon; Tae Rim Oh; Seoyoung Park; Sunghoo Huh; Ji Hyeon Kim; Binh Khanh Mai; Jung Hoon Lee; Se Hyun Kim; Min Jae Lee
Journal:  Neurotherapeutics       Date:  2021-04-21       Impact factor: 6.088

Review 9.  Using miniature brain implants in rodents for novel drug discovery.

Authors:  Ben Waldau
Journal:  Expert Opin Drug Discov       Date:  2019-03-04       Impact factor: 7.050

10.  A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer's disease.

Authors:  Suzanne Reeves; Julie Bertrand; Fabrizia D'Antonio; Emma McLachlan; Akshay Nair; Stuart Brownings; Suki Greaves; Alan Smith; David Taylor; Robert Howard
Journal:  Psychopharmacology (Berl)       Date:  2016-08-01       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.